IgM Antibody Capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA)
Screening for the presence of IgM-class antibodies to Zika virus in patients presenting with symptoms for 14 or more days. Establishment of baseline serologic levels of IgM-class antibodies to Zika virus in women who have traveled to a Zika virus endemic region or who have had sexual exposure to Zika virus and who are considering conception.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This assay is a screening test for IgM-class antibodies to Zika virus. A presumptive positive result by this assay is not diagnostic for Zika virus infection and requires confirmatory testing by plaque reduction neutralization testing (PRNT) performed at the CDC or a CDC-designated laboratory. Confirmatory testing by a molecular assay for detection of Zika virus RNA may also be considered.
This assay should be used in patients presenting at least 2 weeks postsymptom onset or last possible exposure to Zika virus. Reverse transcription-polymerase chain reaction (RT-PCR) for Zika virus RNA detection should be ordered in patients with less than 2 weeks of symptoms or postexposure.
A single negative result by the Zika IgM ELISA should not be used to rule-out infection as the specimen may have been collected prior to the development of detectable antibodies.
2 - 5 days
Collect specimen in SST or red top tube. Centrifuge, aliquot serum into a plastic screw capped vial, and freeze.
Due to similar clinical presentation and cross reactivity, testing for IgM-class antibodies to dengue virus, concurrently with Zika virus IgM testing, is recommended (Dengue Virus Antibody/Antigen Panel, Serum). Test sent to Mayo Medical Laboratories.